Wide World of Stocks Debuts to Showcase Microcap Equities

PORT JEFFERSON, N.Y.--(BUSINESS WIRE)--Wide World of Stocks, a new nationally syndicated television and website program that seeks to showcase undervalued microcap stocks, will launch its 30-minute taped television show and webcast, at www.wideworldofstocks.com, this week. The first company to be featured will be Viral Genetics, Inc. (VRAL.PK), a biotechnology company that develops drug compounds for auto-immune diseases.

The program is in the final stages of legal department approval at three major networks and two cable channels and is expected to be accessible to over 95 million homes nationwide. A broadcast schedule will be posted online as soon as available. Interested parties can register now at the show’s website to receive an alert when the broadcast schedule goes live.

During the first episode, Viral Genetics’ CEO, Haig Keledjian, will discuss his company’s progress in developing a drug therapy to potentially treat HIV/AIDS. The conversation will highlight Viral Genetics’ successful international human clinical trials and plans for commercializing the company’s drug compound. Mr. Keledjian will also discuss the Viral Genetics’ pursuit of treatments for Lyme Disease. Mr. Keledjian also will talk about the company’s two recent additions to the company’s advisory board -- internationally recognized drug development expert Dr. Leslie Z. Benet, and Dr. Luc Montagnier, a 2008 Nobel Prize winner for his role in discovering HIV.

Wide World of Stocks will be hosted by Damon Roberts with co-hosts Rick Perry and Thomas McCarthy, "The Dean" of CollegeStock.com.

Damon Roberts is CEO of Sports Internet Solutions Inc, a comprehensive sports analysis and entertainment company, providing pay-per-view sports news and advice online. Mr. Roberts is also the Sunday morning host of the GameTimeInfo Pregame Football Show, seen in over 95 million homes on the ION Television Network. His website www.gametimeinfo.com has 250,000 subscribers.

Co-Host Rick Perry is a managing director of Institutional Analyst Inc., an investment research and investor relations firm, as well as an editor of eight industry specific investment reviews. He worked for a number of investment firms prior to launching his own investment firm in 1995. He is the founder of the Chicago Stock, Bond & Futures Association and heads Blank Check Capital Corp. Mr. Perry also hosts a website at www.nationalstockreview.com that has approximately 200,000 subscribers comprised of personal and institutional investors.

Thomas McCarthy, known as "The Dean," has a network of over 100,000 followers throughout the www.CollegeStock.com community. CollegeStock.com is the Internet’s #1 destination for stock market education. The Dean of CollegeStock.com goes beyond anything taught in school with a focus on real-time trends in the capital markets.

About Viral Genetics, Inc.:

Viral Genetics, Inc. is engaged in the discovery and development of immune-based therapies for HIV/AIDS and other autoimmune diseases using its thymus nuclear protein compound (TNP). Viral Genetics believes that its investigational HIV/AIDS drug based on TNP, called VGV-1, represents a unique approach to treating HIV/AIDS that focuses on boosting the immune system to allow the body to fight HIV more efficiently. See: www.viralgenetics.com. None of the information contained on this website is incorporated by reference herein.

Not a Broker/Dealer or Financial Advisor:

We are not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be a Registered Broker/Dealer or Financial Advisor. All materials presented in this press release, television show and on our website are not to be regarded as investment advice and are only for informative purposes. Readers should verify all claims and do their own due diligence before investing in featured companies. Investing in small-cap, micro cap and penny stock securities is speculative and carries a high degree of risk.

No Offer of Securities:

None of the information featured in this press release constitutes an offer or solicitation to purchase or to sell any securities of Viral Genetics, Inc.

Compensation:

An Affiliate of our Company has agreed to provide consulting services to Viral Genetics, Inc. in exchange for up to 19 million shares of common stock and 12 million warrants of Viral Genetics, Inc. upon the completion of certain milestones. This is an inherent conflict of interest.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:

Information presented in this press release contains "forward looking statements" within the meaning of Section 27A of the Securities Exchange Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results.

None of the information contained on our website, www.wideworldofstocks.com, is incorporated by reference herein.